RDHL on Nasdaq

RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a pharmaceutical preparations company, listed on Nasdaq (RDHL).1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Coya Therapeutics, Inc., Cogent Biosciences, Inc. or Roivant, or pick any stock.

  • TickerRDHL on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael2
  • Business address21 Ha'Arba'A Street, Tel Aviv, L3 647392
  • Filer categoryNon-accelerated filer2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Our legal and commercial name is RedHill Biopharma Ltd. Our company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. Our principal executive offices are located at 21 Ha’arba’a Street, Tel-Aviv, Israel, and our telephone number is +972-3-5413131.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

60.3%Gross margin4
-181.7%Operating margin4
-102.8%Net margin4
23.2%Revenue growth, 20244
-$9.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue19¢$3.2M
  • Research and development10¢$1.6M
  • Selling, general and admin58¢$9.6M
  • Interest13¢$2.1M

Out of $8.0M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$8.0M in 2024−4% since 2018
0$25.0M$50.0M$75.0M$100.0M2018: $8.4M$8.4M20182019: $6.3M$6.3M2019−25%2020: $64.4M$64.4M2020+923%2021: $85.8M$85.8M2021+33%2022: $61.8M$61.8M2022−28%2023: $6.5M$6.5M2023−89%2024: $8.0M$8.0M2024+23%
Gross profit56784$4.9M in 2024−12% since 2018
0$10.0M$20.0M$30.0M$40.0M2018: $5.5M$5.5M20182019: $4.0M$4.0M2019−27%2020: $27.5M$27.5M2020+581%2021: $36.4M$36.4M2021+32%2022: $28.5M$28.5M2022−22%2023: $3.1M$3.1M2023−89%2024: $4.9M$4.9M2024+58%
Operating income56784-$14.6M in 2024−63% since 2018
-$100.0M-$75.0M-$50.0M-$25.0M0$25.0M2018: -$39.3M-$39.3M20182019: -$43.2M-$43.2M2019+10%2020: -$63.7M-$63.7M2020+47%2021: -$81.1M-$81.1M2021+27%2022: -$42.8M-$42.8M2022−47%2023: $12.6M$12.6M20232024: -$14.6M-$14.6M2024
Net income56784-$8.3M in 2024−79% since 2018
-$100.0M-$50.0M0$50.0M2018: -$38.8M-$38.8M20182019: -$42.3M-$42.3M2019+9%2020: -$76.2M-$76.2M2020+80%2021: -$97.7M-$97.7M2021+28%2022: -$71.7M-$71.7M2022−27%2023: $23.9M$23.9M20232024: -$8.3M-$8.3M2024

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
REVENUES$286.0K
RESEARCH AND DEVELOPMENT EXPENSES$2.0M$1.6M$3.5M
GENERAL, ADMINISTRATIVE, BUSINESS AND DEVELOPMENT EXPENSES$6.2M$4.9M$6.0M
SHARE OF PROFIT OF JOINT VENTURE-$33.0K
OPERATING LOSS-$7.9M-$6.5M-$9.5M
FINANCIAL INCOME$1.3M$8.3M$301.0K
FINANCIAL EXPENSES$1.5M$1.5M$9.3M
FINANCIAL INCOME (EXPENSES), net-$138.0K$6.8M-$8.9M
INCOME (LOSS) FROM CONTINUING OPERATIONS-$8.1M$360.0K-$18.5M
INCOME(LOSS) FROM DISCONTINUED OPERATIONS$7.7M-$8.6M$42.4M
INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE YEAR-$429.0K-$8.3M$23.9M
LOSS PER ORDINARY SHARE FROM CONTINUING OPERATION, basic (U.S. dollars)$0.00$0.00-$0.01
LOSS PER ORDINARY SHARE FROM CONTINUING OPERATION, diluted (U.S. dollars)$0.00$0.00-$0.01
EARNINGS (LOSS) PER ORDINARY SHARE FROM DISCONTINUED OPERATION, basic (U.S. dollars)$0.00$0.00$0.02
EARNINGS (LOSS) PER ORDINARY SHARE FROM DISCONTINUED OPERATION, diluted (U.S. dollars)$0.00$0.00$0.02
EARNINGS (LOSS) PER ORDINARY SHARE, basic (U.S. dollars)$0.00$0.00$0.01
EARNINGS (LOSS) PER ORDINARY SHARE, diluted (U.S. dollars)$0.00$0.00$0.01

Compare RedHill Biopharma Ltd. with another company

Corporate structure

RedHill Biopharma Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of RedHill Biopharma Ltd.

  • YA II PN, Ltd. Filed SCHEDULE 13G on RedHill Biopharma Ltd., latest Dec 23, 2025
  • Alumni Capital LP Filed SCHEDULE 13G on RedHill Biopharma Ltd., latest Oct 20, 2025
  • CVI Investments, Inc. Filed SC 13G/A on RedHill Biopharma Ltd., latest Nov 14, 2024 (2 filings since Feb 1, 2024)
  • Prieto Wood &. Boyer P.a. Quintairos Filed SCHEDULE 13D on RedHill Biopharma Ltd., latest Aug 7, 2024
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G on RedHill Biopharma Ltd., latest Feb 2, 2024
  • Empery Asset Management, LP Filed SC 13G/A on RedHill Biopharma Ltd., latest Jan 8, 2024 (2 filings since Jan 13, 2023)
  • SABBY MANAGEMENT, LLC Filed SC 13G/A on RedHill Biopharma Ltd., latest Jan 2, 2024 (2 filings since Jan 4, 2023)
  • Cosmo Pharmaceuticals N.V. Filed SC 13G on RedHill Biopharma Ltd., latest Mar 7, 2022
  • IBEX INVESTORS LLC Filed SC 13G/A on RedHill Biopharma Ltd., latest Jan 27, 2022
  • RedHill Biopharma Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What RedHill Biopharma Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$135.0K4 Dec 31, 2024$193.0K4 Dec 31, 2023−30.1%
Operating-lease assets (leased space)$302.0K4 Dec 31, 2024$989.0K4 Dec 31, 2023−69.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.6M4 Dec 31, 2024$5.6M4 Dec 31, 2023−17.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$5.5M4 Dec 31, 2024$5.6M4 Dec 31, 2023−0.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.7M4 Dec 31, 2024$4.4M4 Dec 31, 2023−16.8%

Leadership

Who has led RedHill Biopharma Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dror Ben-Asher2026–now

Chief financial officer

  1. Razi Ingber2026–now

Chief operating officer

  1. Gilead Raday2026–now
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerReza Fathi named Nov 22, 2021 to Feb 5, 202420
  • Executive OfficerJune Almenoff named Nov 22, 202121
  • Executive OfficerMicha Ben Chorin named Nov 22, 202121
  • DirectorAlla Felder named Nov 22, 2021 to Feb 5, 202420
  • DirectorEric Swenden named Nov 22, 2021 to Feb 5, 202420
  • DirectorKenneth Reed named Nov 22, 2021 to Feb 5, 202420

Timeline

  1. Mar 18, 2026New chief executive Dror Ben-Asher becomes CEO11

Filings

333 filings to the SEC since October 2021: 5 annual reports, 13 insider forms, 12 large holders, 4 private raises, 299 other. The latest 20:

  1. Oct 13, 20266-K EDGAR
  2. Oct 13, 2026424B5 EDGAR
  3. Oct 7, 20266-K EDGAR
  4. Oct 6, 20264 EDGAR
  5. Sep 30, 20266-K EDGAR
  6. Sep 30, 20266-K EDGAR
  7. Sep 1, 20266-K EDGAR
  8. Aug 31, 20266-K EDGAR
  9. Aug 7, 20266-K EDGAR
  10. Aug 6, 20266-K EDGAR
  11. Jul 28, 20266-K EDGAR
  12. Jul 14, 2026424B3 EDGAR
  13. Jul 13, 2026EFFECT EDGAR
  14. Jul 13, 20264 EDGAR
  15. Jul 2, 2026F-3 EDGAR
  16. Jul 1, 20266-K EDGAR
  17. Jun 29, 20266-K EDGAR
  18. Jun 29, 2026424B5 EDGAR
  19. Jun 25, 20266-K EDGAR
  20. Jun 22, 20266-K EDGAR

The 333 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 10, 2026Raday GileadChief Operating OfficerSale14,130,000Form 4
Apr 6, 2026Raday GileadChief Operating OfficerSale15,740,000Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 25, 2024Raised $10 million in a private offering of equity Form D: 5 investors so far Form D
  2. Sep 28, 2023Raised $4 million in a private offering of equity Form D: 3 investors so far Form D
  3. Jul 21, 2023Raised $2.7 million in a private offering of equity Form D: 1 investor so far Form D
  4. Nov 8, 2021Raised $5 million in a private offering of equity Form D: $10 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Yorkville Advisors Global, LP122,131$106.7K0.1%−228,739
Gagnon Securities LLC88,405$74.7K0.0%No change
Citadel Advisors LLC65,321$55.2K0.0%+44,648
Rhumbline Advisers13,755$11.6K0.0%+8,639
Lido Advisors, LLC11,009$9.3K0.0%New
GAMMA Investing LLC6,957$5.9K0.0%+273
Citigroup Inc4,378$3.7K0.0%New
Federation des caisses Desjardins du Quebec3,388$2.9K0.0%No change
UBS Group AG100$850.0%−726
SBI Securities Co., Ltd.15$130.0%+11
Smartleaf Asset Management LLC5$40.0%No change
Vermillion Wealth Management, Inc.2$20.0%No change
Morgan Stanley1$10.0%No change
Royal Bank Of Canada351$00.0%+350

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How RedHill Biopharma Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRedHill Biopharma Ltd.1
  • CIK0001553846
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company3
  • Incorporated inIsrael3
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address21 Ha'Arba'A Street, Tel Aviv, L3 647391
  • Phone972-3-541-31311
  • Shares outstanding50,923,261,000 shares as of Dec 31, 20253
  • AuditorKesselman & Kesselman, Tel-Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 1, 20121
  • Filings1,027 in all: 6-K (765), 424B5 (34), SC 13G/A (29), SC 13G (23), EFFECT (18), 424B3 (16), UPLOAD (16), 20-F (14)1
    All 35 form types

    CT ORDER (14), S-8 (13), CORRESP (12), 3 (10), F-3 (10), FWP (10), D (6), 6-K/A (5), 20-F/A (4), POS AM (4), 4 (3), F-1 (3), DRS/A (2), SC 13D/A (2), SCHEDULE 13G (2), 20FR12B (1), CERTNAS (1), DRS (1), DRSLTR (1), F-1/A (1), F-3/A (1), F-6 (1), F-6EF (1), SC 13D (1), SC TO-I (1), SC TO-I/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Apr 27, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing ten thousand (10,000) Ordinary Shares (1)RDHLNASDAQ
Ordinary Shares, par value NIS 0.01 per share (2)

From the cover page of the 20-F filed Apr 27, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30